TITLE

Aspects of Prophylactic Vaccination against Cervical Cancer and Other Human Papillomavirus-Related Cancers in Developing Countries

AUTHOR(S)
Natunen, Kari; Lehtinen, Johannes; Namujju, Proscovia; Sellors, John; Lehtinen, Matti
PUB. DATE
January 2011
SOURCE
Infectious Diseases in Obstetrics & Gynecology;2011, Vol. 2011, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cervical cancer and other human papillomavirus- (HPV-) related cancers are preventable, but preventive measures implemented in developing countries and especially in low-income rural regions have not been effective. Cervical cancer burden derived from sexually transmitted HPV infections is the heaviest in developing countries, and a dramatic increase in the number of cervical cancer cases is predicted, if no intervention is implemented in the near future. HPV vaccines offer an efficient way to prevent related cancers. Recently implemented school-based HPV vaccination demonstration programmes can help tackle the challenges linked with vaccine coverage, and access to vaccination and health services, but prevention strategies need to be modified according to regional characteristics. In urban regions WHO-recommended vaccination strategies might be enough to significantly reduce HPV-related disease burden, but in the rural regions additional vaccination strategies, vaccinating both sexes rather than only females when school attendance is the highest and applying a two-dose regime, need to be considered. From the point of view of both public health and ethics identification of the most effective prevention strategies is pivotal, especially when access to health services is limited. Considering cost-effectiveness versus justice further research on optional vaccination strategies is warranted.
ACCESSION #
79168807

 

Related Articles

  • Formative research to shape HPV vaccine introduction strategies in Peru. Bartolini, Rosario M.; Drake, Jennifer Kidwell; Creed-Kanashiro, Hilary M.; Díaz-Otoya, Margarita M.; Mosqueira-Lovón, Nelly Rocío; Penny, Mary E.; Winkler, Jennifer L.; LaMontagne, Scott; Bingham, Allison // Salud Pública de México;may2010, Vol. 52 Issue 3, p226 

    Objetivo. Comprender el contexto sociocultural, las capacidades del sistema de salud y las condiciones políticas vinculadas al cáncer cervical y a la vacuna contra el VPH para diseñar una estrategia apropiada de introducción de la vacuna contra el VPH. Material y métodos....

  • Epidemiology of cervical cancer in Latin America. Capote Negrin, Luis G. // Ecancermedicalscience;2015, Vol. 9 Issue 577-607, p1 

    The basic aspects of the descriptive epidemiology of cervical cancer in Latin America are presented. A decrease in the incidence and mortality rates has been observed in the period from 2000 to 2012 in all countries across the region, this has not occurred at the same proportions, and in many...

  • Genetic Variability in L1 and L2 Genes of HPV-16 and HPV-58 in Southwest China. Yaofei Yue; Hongying Yang; Kun Wu; Lijuan Yang; Junying Chen; Xinwei Huang; Yue Pan; Youqing Ruan; Yujiao Zhao; Xinan Shi; Qiangming Sun; Qihan Li // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    HPV account for most of the incidence of cervical cancer. Approximately 90% of anal cancers and a smaller subset (<50%) of other cancers (oropharyngeal, penile, vaginal, vulvar) are also attributed to HPV. The L1 protein comprising HPV vaccine formulations elicits high-titre neutralizing...

  • Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Brotherton, Julia M. L.; Kaldor, John M.; Garland, Suzanne M. // Sexual Health (14485028);Sep2010, Vol. 7 Issue 3, p310 

    The article provides information on a study which proposed a possible multifaceted strategy to human papillomavirus (HPV) related surveillance in Australia following the adoption of a national HPV vaccination program. Main components discussed in detail are monitoring of vaccine coverage,...

  • DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies. Kyusun Torque Han; Jeong-Im Sin // Clinical & Experimental Vaccine Research;Jul2013, Vol. 2 Issue 2, p106 

    Human papillomavirus (HPV) infection is a major cause of cervical cancer and its precancerous diseases. Cervical cancer is the second deadliest cancer killer among women worldwide. Moreover, HPV is also known to be a causative agent of oral, pharyngeal, anal and genital cancer. Recent...

  • Knowledge of human papillomavirus (HPV) and the HPV vaccine in a national sample of Australian men and women. Pitts, Marian K.; Heywood, Wendy; Ryall, Richard; Smith, Anthony M.; Shelley, Julia M.; Richters, Juliet; Simpson, Judy M. // Sexual Health (14485028);Sep2010, Vol. 7 Issue 3, p299 

    The article presents information on a study which investigated human papillomavirus (HPV) knowledge following the introduction of a national HPV vaccination program in Australia using a representational sample of men and women. Data collection was through computer-assisted telephone interview...

  • Cost-effective cervical cancer prevention possible in Brazil.  // PharmacoEconomics & Outcomes News;9/8/2007, Issue 536, p4 

    The article discusses research being done on the development of a cost effective strategy for cervical cancer prevention in Brazil. It references a study by S. J. Goldie et al. published in the August 2007 issue of the "Vaccine." The researchers concluded that a human papillomavirus (HPV)...

  • Identification of human papillomaviruses from formalin-fixed, paraffin-embedded pre-cancer and invasive cervical cancer specimens in Zambia: a cross-sectional study. Bateman, Allen C.; Katundu, Katundu; Polepole, Pascal; Shibemba, Aaron; Mwanahamuntu, Mulindi; Dittmer, Dirk P.; Parham, Groesbeck P.; Chibwesha, Carla J. // Virology Journal;2015, Vol. 12 Issue 1, p81 

    Background The most common human papillomavirus (HPV) genotypes isolated from cervical cancer in select African countries are HPV-16, HPV-18, HPV-35, and HPV-45, but the most common genotypes in Zambia are unknown. The overall objective of this study was to assess the potential impact of current...

  • Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. Solares, Ana M.; Baladron, Idania; Ramos, Thelvia; Valenzuela, Carmen; Borbon, Zaida; Fanjull, Sonia; Gonzalez, Leonardo; Castillo, Dagnelia; Esmir, Julio; Granadillo, Milaid; Batte, Aileen; Cintado, Alberto; Ale, Mayte; de Cossio, Maria E. Fernandez; Ferrer, Annia; Torrens, Isis; Lopez-Saura, Pedro // ISRN Obstetrics & Gynecology;2011, Special section p1 

    Objective. CIGB-228 is a novel therapeutic vaccine consisting of HLA-restricted HPV16 E7 epitope adjuvated with VSSP. This trial was designed to evaluate the toxicity, safety, immunogenicity, HPV clearance, and lesion regression. Methods. Seven women were entered. All were HLA-A2 positive, had...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics